Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
Go back to Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland| (NASDAQ: BLTE) | Delayed: 145.09 -1.98 (1.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $147.07 | 52 Week High | $ | |||
| Open | $145.94 | 52 Week Low | $ | |||
| Day High | $148.65 | P/E | N/A | |||
| Day Low | $144.64 | EPS | $ | |||
| Volume | 214,856 | |||||
